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Information on the prevalence of infection with
primarily isoniazid-resistant tubercle bacilli among
tuberculous patients is available from a number of
countries. Figures have been reported from several
centres, including New York City (Chaves et al.,
1955 1956), Great Britain (Fox et al., 1957), the
Province of Quebec (Frappie, Desjardins & Panisset,
1957), Germany (Meissner, 1958), Austria
(Dissmann & Iglauer, 1960), Madras City
(Tuberculosis Chemotherapy Centre, 1959, 1960),
Ashanti, Ghana (Bell & Brown, 1960) and Paris
(Thibier et al., 1960). Rist & Crofton (1960) have
recently published the results of a world survey.
Pepys, Mitchison & Kinsley (1960) have
reported figures for patients with pulmonary
tuberculosis presumed to have had no previous
chemotherapy presenting for treatment in East
Africa. Their figures, however, do not indicate the
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extent of the radiographic lesion, the extent of cavitation or the bacterial content of the
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showing a greater preponderance of young males than the S patients. As to the second
comparison, statistically significant differences in the bacteriological response to treatment
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true prevalence of primary isoniazid-resistant
infections as a number of patients subsequently
confessed to having had previous chemotherapy.
There is, however, very little information on the
effects of treatment with isoniazid, alone or in
combination, in patients infected with isoniazid-
resistant tubercle bacilli. A report from the
Tuberculosis Chemotherapy Centre, Madras
(Tuberculosis Chemotherapy Centre, 1959) has
described the results of treatment with isoniazid plus
p-aminosalicylic acid (PAS) of six of seven such
patients and another report (Tuberculosis
Chemotherapy Centre, 1960) summarized the
disease status at one year for 20 patients, 14 treated
with isoniazid alone and six with isoniazid plus PAS.
The present paper studies the pretreatment clinical
and bacteriological status of these 20 patients in the
1960 report and their progress during a year of
treatment, and compares them with those of the 315
patients excreting isoniazid-sensitive organisms
when they were admitted to the same study.
In all, 341 patients aged 12 years or more, with
newly diagnosed active pulmonary tuberculosis,
were allocated at random to four regimens of
chemotherapy of 12 months (Tuberculosis Chemo-
therapy Centre, 1960). The four regimens were:
PH (96 patients). Isoniazid 3.9-5.5 mg/kg body-
weight daily plus PAS (sodium) 0.2-0.3 g/kg body-
weight daily, divided into two doses, by mouth—
i.e., 200  mg of isoniazid plus 10g of PAS (sodium)
a day for a patient weighing 100 lb. (45.4 kg).
HI-1 (75 patients). Isoniazid alone, 7.8-9.6 mg/
kg body-weight daily, divided into two doses, by
mouth —i.e., 400 mg of isoniazid a day for a patient
weighing 100 lb.
HI-2 (75 patients). Isoniaid alone, 7.8-9.6 mg/
kg body-weight daily, divided into two doses, by
mouth—i.e., 400 mg of isoniazid a day for a patient
weighing 100 lb.
H (95 patients). Isoniazid alone, 3.9-5.5 mg/kg
body-weight daily, divided into two doses, by mouth
—i.e., 200 mg of isoniazid a day for a patient
weighing 100 lb.
Six patients (3 HI-1, 1 HI-2, 2H) have been
excluded, three because they had received previous
chemotherapy, which included isoniazid, for a
period of more than two weeks and three of reasons
given in the earlier report (Tuberculosis
Chemotherapy Centre, 1960). There remain 315
patients (90 PH, 70 HI-1, 68 HI-2, 87 H) infected
with isoniazid-sensitive tubercle bacilli, the “S”
patients, and 20 (6 PH, 2 HI-1, 6 HI-2, 6 H) infected
with isoniazid-resistant organisms, the “R” patients.
The patients were treated in their homes, the great
majority attending the Centre weekly for a supply
of medicine. The full details of the management have
been given elsewhere (Tuberculosis Chemotherapy
Centre, 1960).
The investigations before treatment included a
full-plate chest radiograph, measurement of the
weight, measurement of the erythrocyte
sedimentation rate (ESR Westergren 200 mm,
reading in mm at one hour), examination of four
sputum specimens by smear and culture, tests of
sensitivity to isoniazid on two cultures and
qualitative estimation of the catalase activity of both
of them and semi-quantitative estimation on all
resistant cultures and on a sample of sensitive
cultures. One of the cultures from each patient was
tested for virulence in the guinea-pig and studied
by a series of identification tests. Investigations
during treatment included a monthly radiograph, two
examinations of the sputum each month by smear
and culture and, from the third month, a pair of
laryngeal swabs by culture, also. A test of sensitivity
to isoniazid and a qualitative catalase test were
performed on one positive culture at the end of each
month. If the culture was isoniazid-resistant, a semi-
quantitative catalase test was undertaken as well.
The patient’s rate of inactivation of isoniazid was
also determined at some time during the second six
months of treatment.
Changes of chemotherapy
The reasons for which the chemotherapy was
changed were drug toxicity, a clear-cut radiographic
extension of the disease, confirmed by an
independent assessor (Dr K. S.Sanjivi), or serious
clinical deterioration.
BACTERIOLOGICAL PROCEDURES
Bacterial content of sputum
Sputum smears were examined by fluorescence
microscopy and were graded as 3-plus (heavy),
2-plus (moderate), 1-plus (scanty) and negative. The
specimens were treated with 4% sodium hydroxide,
washed with distilled water and cultured on
Lowenstein-Jensen medium without potato starch
(Jensen, 1955). The cultures were examined weekly
for eight to nine weeks (Tuberculosis Chemotherapy
Centre, 1959).
Sensitivity tests
Tests of sensitivity of isoniazid were set up two
or three days after the cultures became positive. If
growth was insufficient, the cultures were
reincubated to allow enough organisms to grow for
preparation of the inoculum. The inoculum
suspension was made by adding approximately 2
mg (moist weight) of bacilli, obtained a represen-
tative sample from all parts of the growth, to 1/4-
ounce (approximately 10-ml) screw-capped bottles
containing 0.5 ml of sterile distilled water and glass
beads, and then shaking the bottle mechanically for
one minute. Standard 3-mm loopfuls of this
suspension were inoculated on to a series of slopes
of Lowenstein-Jensen medium containing 0.2, 1, 5
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and 50 isoniazid, as well as on to a drug-free slope
as a control. The standard sensitive strain of
Mycobacterium tuberculosis, H37Rv, was also set
up with each series of tests, on slopes containing
0.025, 0.05, 0.1, 0.2 and 1 mg/ml isoniazid.
Definitions of isoniazid resistance
In the following definitions “growth” has been
defined as 20 or more colonies. If the control (drug-
free) slope yielded 100 or fewer colonies the test
was repeated.
Before treatment, resistance to isoniazid was
defined as:
(a) Growth on 1 mg/ml or a higher concentration,
even if the result of a test on a second culture was
sensitive.
(b)Growth on 0.2 mg/ml, followed by the same
result on a repeat test on the same culture, even if
the result of a test on a second culture was sensitive.
(c) Growth on 0.2 mg/ml, for two separate
cultures, irrespective of the results of repeat tests.
During treatment, resistance to isoniazid was
defined as:
Growth on 0.2 mg/ml or a higher concentration,
irrespective of the results of repeat tests.
Catalase activity
Qualitative and semi-quantitative estimations of
the catalase activity of cultures were carried out by
the methods previously described (Tuberculosis
Chemotherapy Centre, 1959). The catalase activity
on the drug-free slope was estimated by both
methods and that of the growth of 20 or more
colonies on the isoniazid-containing slopes by the
qualitative method only.
Identification tests
The cultures were examined by the following in
vitro identification tests: (a) bacterial morphology;
(b) colonial morphology on Lowenstein-Jensen
slopes and on 7H-10 oleic-acid-albumin plates; (c)
growth at 230 C; (d) pigment production; (e) catalase
activity on the drug-free slope and on the 50 mg/ml
isoniazid slope; and (f) niacin production. The meth-
ods have been described by Thomas et al. (1961 1).
Virulence tests
Cultures were tested for virulence in the guinea-
pig as described by Mitchison et al. (1960). In brief,
1 mg (moist weight) of a pretreatment culture of
tubercle bacilli was inoculated intramuscularly into
each of two guinea-pigs, one of which was killed at
6 weeks and the other at 12 weeks. At post-mortem
examination the total extent of tuberculous disease
in the spleen, liver, lungs and local glands was
assessed as a score ranging from 0 to 100. The ratio
of the score to the survival time in days was
determined for each guinea-pig. The measure of
virulence employed was the mean of the square root
of the ratios for the two guinea-pigs which has been
termed the root-index of virulence (Mitchison et al.,
1961). Values of 0-0.59 were considered to indicate
low virulence, 0.60-0.89 moderate virulence and
0.90 or above high virulence.
The majority of the virulence tests were done at
the Microbiological Research Establishment, Porton,
England; the results of the smaller series of tests
done in Madras were adjusted to those obtained at
Porton as described by Mitchison et al. (1961).
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RESULTS
Prevalence of infection with isoniazid-resistant
tubercle bacilli
All the 341 patients admitted to the study were
interrogated on several occasions during the course
of treatment, as their relationship of trust with the
Centre’s staff became more and more firmly
established, to discover whether they had had
previous chemotherapy and were concealing the
fact. Relatives and, if necessary, friends were
approached and dispensary cards from other
hospitals and prescriptions from private doctors were
scrutinized. One patient excreting isoniazid-
sensitive and two excreting isoniazid-resistant
tubercle bacilli admitted that they had had previous
chemotherapy of more than two weeks’ duration.
Of the remaining 338 patients, 20, the “R” patients,
had isoniazid-resistant organisms; and one had had
a week of streptomycin plus isoniazid. It is
considered that these 20 (5.9%) patients (6 PH, 2
HI-1, 6 HI-2, 6 H) out of the 338 who had had either
no previous chemotherapy, or very little, had been
infected with isoniazid-resistant organisms. The
remaining patients had fully sensitive strains
although seven of them had had up to two weeks’
chemotherapy which included isoniazid.
1
 See article on page 747.
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Among the patients classified as having sensitive
organisms before treatment, there were seven with a
culture which yielded growth of 20 or more colonies
on 0.2 µg/ml but not on 1 µg/ml isoniazid, and with
no growth on 0.2 µg/ml in a repeat test of this
culture or in the test on the second culture from the
patient. These seven patients responded to chemo-
therapy as favourably as the other patients who were
classified as having initially sensitive organisms.
Levels of resistance of the pretreatment cultures
Table 1 gives the minimal inhibitory concentra-
tions (MICs) of isoniaxid of the two cultures isolated
before treatment from each of the 20 “ R ” patients.
It will be seen that eight of these patients yielded
two highly resistant cultures (MICs of 5 µg/ml or
more) and that six patients yielded two cultures of
low resistance (MICs of 1 µg/ml). There were three
patients who yielded one resistant and one sensitive
culture.
Identification tests
From 18 of the 20 patients an isoniazid-resistant
culture isolated before the start of treatment was
examined by the full series of identification tests
(see page 809), with the exception, in five cases, of
the test for growth at 23°C. All tests performed on
these 18 cultures gave results typical of Myco. tuber-
culosis and, since they were niacin-positive, they have
been classified as Myco. tuberculosis var. hominis. The
remaining two cultures were not submitted to a full
range of tests. One of them was tested for virulence
TABLE 1
MINIMAL INHIBITORY CONCENTRATION OF ISONIAZID
OF TWO CULTURES ISOLATED BEFORE TREATMENT
FROM PATIENTS INFECTED WITH ISONIAZID-
RESISTANT TUBERCLE BACILLI
Total            20
in the guinea-pig and was found to be highly virulent
(root-index of 1.12). This culture has, therefore, also
been regarded as Myco. tuberculosis. The other
pretreatment culture for the identification tests
became contaminated after the sensitivity test had
been performed and further investigations were not
possible (the second pretreatment culture from the
patient was no longer available). A culture from this
patient at the end of 12 months’ treatment was
examined by the full series of tests and identified
as Myco. tuberculosis var. hominis.
PRETREATMENT COMPARISONS
Sex and age
There were major differences between the S and R
patients in the age and sex distributions. Of the
315 S patients, 199 (63 %) were males, as compared
with 18 (90%) of the 20 R patients. This difference
attains statistical significance (P=0.01). Table 2
shows the age distribution of the male patients.
Of the 199 S males 113 (57 %) were less than 35 years
old, as compared with 15 (83%) of the 18 R males.
This difference also attains statistical significance
(P ~ 0.02). Of the 116 S females, 85 (73%) were less
than 35 years old; the R females were aged 13 and
23 years, respectively.
Clinical condition
Table 3 presents three pretreatment radiographic
assessments made by an independent observer,
Dr Raj Narain, who was unaware of the classification
as S or R of any patient, and the pretreatment
bacterial content of the sputum. Considering the
TABLE 2
AGE DISTRIBUTION OF THE MALE PATIENTS
Estimated S patients R patients
age
(years)
Total 199 101 18 100
a The parentheses indicate percentages based on fewer than
25 observations.
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TABLE 3
CONDITION ON ADMISSION TO TREATMENT
Condition
Extent of cavitation:
Nil
Slight
Moderate
Extensive
Total extent of disease :
Trivial or slight
Limited or moderate
Extensive or gross
Number of lung zones involved in disease:
1 or 2
3 or 4
5 or 6
Bacterial content of sputum : b
Direct smear negative
Direct smear positive:
1-plus (scanty)
2-plus (moderate)
3-plus (heavy)
Total
S patients R patients
No. % No. %
22 7 2 (10)a
94 30 3 (15)
182 51 13 (65)
37 12 2 (10)
26 8
196 62
93 30
61 19
126 40
128 41
50 18
57 18
96 30
112 36
315 100
1 (5)
12 (60)
7 (35)
4 (20)
10 (50)
6 (30)
2 (10)
2 (10)
9 (45)
7 (35)
20 100
a The parentheses indicate percentages based on fewer than
25 observations.
b Based on a single collection specimen,
extent of cavitation, 12 % of the 315 S and 10 % of the
20 R patients had extensive cavitation and 51% and
65%, respectively, had moderate cavitation. There
was little difference in terms of the total extent of the
radiographic lesion, 30% of the S patients having
extensive or gross disease, as compared with 35 % of
the R patients, and, at the other extreme, 8 % of the
S patients and 5% of the R patients having trivial
or slight lesions. The distributions for the number
of lung zones involved in disease were similar,
although rather more of the S patients (41%) than
the R patients (30 %) had 5 or 6 lung zones involved.
The over-all distributions of bacterial content of the
sputum were also similar, but there were fewer
patients in the S series than in the R series with
2-plus and 3-plus direct smear findings (66%, as
compared with 80%).
Rate of inactivation of isoniazid
Estimations of the rate of inactivation of isoniazid
were carried out on 303 of the S patients and on
18 of the R patients by a method described by
Gangadharam et al. (1961).1 Of the S patients 181
(60%) were slow inactivators, as compared with 14
(78 %) of the R patients.
Virulence of the cultures in the guinea-pig
Table 4 gives the distribution of the root-indices
of virulence (defined on page 809) of the strains from
281 S patients and 17 R patients. The mean root-
index of virulence was 0.72 for both series.
TABLE 4
VIRULENCE IN THE GUINEA-PIG OF THE STRAINS
OF TUBERCLE BACILLI FROM THE PATIENTS
ON ADMISSION TO TREATMENT
Root-index
of virulence a
S patients
No. %
0-0.59
(low virulence)
91 32
0.60-0.89 122 43
(moderate virulence)
0.90 and above
(high virulence)
68 24
Total c 231 99
Mean 0.73
R patients
No. %
7 (39) b
3 (44)
3 (17)
18 100
0.71
a The root-indices obtained in the Madras series were ad-
justed to those in the Porton series, as described by Mitchison
et al. (1961).
b The parentheses indicate percentages based on fewer than
25 observations.
CThe virulence of the strain was not determined for 34 S
patients and for 2 R patients.
Catalase activity of the cultures
Qualitative estimations of the catalase activity
were performed on 618 isoniazid-sensitive pretreat-
ment cultures from the 315 S patients and on 39
(36 resistant and three sensitive) of the 40 pretreat-
ment cultures from the 20 R patients. One of the
cultures from the S patients had 3-plus activity,
1 See article on page 765.
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615 had 2-plus and two had l-plus activity. Of the RESPONSE TO TREATMENT
36 msistant cultures tested from the R patients,
29 had 2-plus catalase activity and seven l-plus Since 15 of the 20 R patients were males aged less
activity. The three sensitive cultures had 2-plus than 35 years, analyses (not tabulated here) were
activity. The results of a semiquantitative estima- undertaken to compare the progress of these 15
tion of the cat&se activity were also available for patients and the 113 S males in the same agegroup.
49 cultures obtained from a sample of the same The fhlings  were very similar to those of the com-
number of S patients and for 33 resistant cultures parison of the progress of the full populations of the
obtained from 19 R patients. All the cultures from 20 R and the 315 S patients. The comparisons of the
the S patients had 600/,-100%  activity, whereas of full populations have therefore been presented in
the 33 resistant cultures from the R patients, 23 had the subsequent sections, in which the patients receiv-
60X-100%  catalase activity and 10 (from six ing isoniazid plus PAS in the S group are compared
patients) 20%-50X activity (see Table 10, pages 818- with those receiving the same treatment in the R
819). There was thus some evidence of lesser catalase group, and the S and R patients have been compared
activity of the cultures from the R patients than of for the three isoniazid regimens combined.
those from the S patients.
In summary, there was a much greater prepon- Weight changes
derance of young males among the R patients than There were 80 S and five R patients who received
among the S patients. There was little difference in isoniazid plus PAS for the full 12 months; 92% of
terms of the extent of the radiographic lesion, the the S and all the R patients gained weight, and the
extent of cavitation or the bacterial content of the mean gain in weight was 10.3 lb. for the former and
sputum. The can&se  activity of the pretreatment 9.8 lb. for the latter. Correspondingly, 92% of
cultures from the S patients was, on the average, 167 S patients on isoniazid alone who received the
greater than that of the cultures from the R patients, prescribed chemotherapy for the 12 months gained
but there was no difkence between them in respect weight, as compared with 91% of 11 R patients;
of their virulence in the guinea-pig. the mean gain in weight was 11.0 lb. for the S and
TABLE 5
DISTRIBUTIONS OF THE ERYTHROCYTE SEDIMENTATION RATE ON ADMISSION TO TREATMENT
AND AT 12 MONTHS a
lsoniazid plus PAS lsoniaxid alone
ESR
(mm in 1 hour) S patientsO  adF; / ;+I; ~$lie;
No. % No.
:o;ti~~itZ~~e;  1 ;ytiezstj  m$Z;e;
O-10 0 0 0 co)* 1 5   1 8  1 (17) 3 f / 0 (0) 1 5 6 26 ( 3 ( 21 )
; I
1 1 - 2 0 13 4/  1 (17)124 291  1 (17)1 7 3.1 0 (0)I 44 211 3 (27)
; ; 
21-50 1 23 27 1 0  (0) 1 27 32 1 2 (33) 9 23 1 3 (21)  I 42 20 / 3 (20
I /
61 or more 1 53 69 I 5 (83) 16 19 1  (17) 1153 72 II (79) 1 32 15 / 2 (14)
ChanQe  of chemo-
therapy due to - - / - - 1 2 2 / 1 (77) - - - - 36 18 3
deterioration, and
tuberculous death 1 / 1 (20
T&@ patients 34 199  6I 100 34 180  6 1 0 1 I 212 99 14 loo 212100 14 98
I I
e Ftve  pattents  who died of non-tuberculous conditions, eiQht  patients who had their chemotherapy chanQed  on account of
toxtcity  and aii petients  for whom no results were available have been excluded.
* The parentheses Indicate percentaQes  based on fewer than 26 observations.
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9.7 lb. for the R patients. In the first six months, the
mean weight gains were 9.7 lb. for the S and 9.2 lb.
for the R patients who received isoniazid plus PAS,
and 9.9 lb. for the S and 7.7 lb. for the R patients
on isoniazid alone.
Erythrocyte sedimentation rate
The distributions of the ESRs at the start of
treatment and at 12 months are set out in Table 5.
The S and R series, whether on the combined chemo-
therapy or on isoniazid alone, showed an increase
at 12 months in the proportions of patients with
low ESRs (20 mm or less); the proportions of S and
R patients with low ESRs were similar for the
isoniazid-alone series.
Radiographic changes
The changes in the radiographic appearances were
assessed by an independent observer, Dr Raj Narain,
who was unaware of the treatment series or clinical
details of any patient. In the first six months (Table 6)
97% of 87 S and 83 % of six R patients receiving
isoniazid plus PAS showed radiographic improve-
ment as did 84% of 219 S and 71% of 14 R patients
receiving isoniazid alone. It will be noted that the
proportions showing moderate or greater improve-
ment in the isoniazid-alone series were 68 % for the S
but only 29 % for the R patients. Over the 12-month
period, 94% of 86 S and 67 % of six R patients
receiving isoniazid plus PAS and 77 % of 216 S and
79% of 14 R patients on isoniazid alone showed
radiographic improvement. The proportions showing
moderate or greater improvement in the isoniazid-
alone series were 69 % for the S and 64% for the
R patients. Thus, by 12 months, the evidence of
greater progress in the S patients than in the R
patients receiving isoniazid alone, which was appa-
rent at six months, had largely disappeared.
Changes in cavitation
Table 7 presents the independent assessment of
the changes in cavitation for the 12-month period
TABLE 6
CHANGES IN RADIOGRAPHIC APPEARANCES IN THE FIRST SIX MONTHS AND IN THE 12-MONTH PERIOD a
Period
0-6
months
0-12
months
Moderate or greater improvement
Slight improvement
No change
Deterioration with or without change of chemo-
therapy, or tuberculous death
Total
Moderate or greater improvement
Slight improvement
No change
Deterioration with or without change of chemo-
therapy, or tuberculous death
Total
lsoniazid plus PAS
S pat ients R patients
No. %  No. %
69 79 4 (67) b
15 17 1 (17)
1 1 0 (0)
2 2 1 (17)
87 99 6 101
73 85 4 (67)
8 9 0 (0)
2 2 1 (17)
3 3 1 (17)
86 99 6 101
lsoniazid alone
S patients  R patients
No. %  No. %
149 68 4 (29)
35 16 6 (43)
12 5 1 (7)
23 11 3 (21)
219 100 14 100
150 69 9 (64)
16 7 2 (14)
5 2 0 (0)
45 21 3 (21)
216 99 14 99
a Two separate assessments on standard radiographs. Patients who died of non-tuberculous conditions are excluded after
their death and patients who had their chemotherapy changed or account of toxicity are excluded after the change.,
b The parentheses indicate percentages based on fewer than 25 observations.
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TABLE 7
CHANGES IN CAVITATION IN THE 12-MONTH PERIOD IN PATIENTS WITH CAVITATION
ON ADMISSION TO TREATMENTa
Cavitation disappeared
Cavitation less
Cavitation unchanged or more
Change of chemotherapy due to
deterioration, and tuberculous death
Total patients with cavitation on
admission
lsoniazid plus PAS lsoniazid alone
S patients
No. %
R patients S patients
No. % No. %
50 64 2 (33)a 109 54
20 26 3 (50) 46 23
6 8 0 (0) 9 4
2 3 1 (17) 38 19
70 101 6 100 202 100
R patients
No. %
2 (17)
6 (50)
1 (8)
3 (25)
12 100
a Assessment on standard radiographs on admission to treatment and at 12 months. Patients
who died of non-tuberculous conditions and patients who had their chemotherapy changed on
account of toxicity have been excluded.
b The parentheses indicate percentages based on fewer than 25 observations.
for the patients with cavitation on admission to and 17 %. Thus, the cavities disappeared in a greater
treatment. Of the 78 S patients on isoniazid plus proportion of S patients than R patients. However,
PAS, 64% had no cavitation at 12 months, as com- there was little difference between these two groups
pared with 33 % of six R patients. The corresponding of patients, whether on isoniazid alone or on the
proportions for the 202 S and 12 R patients who combined chemotherapy, if reduction and disappear-
received isoniazid alone for the whole year were 54 % ance of cavitation were considered together.
TABLE 8
PATIENTS WITH NEGATIVE CULTURES OF SINGLE COLLECTION SPECIMENS OF SPUTUM TAKEN
AT 3-MONTHLY INTERVALS
chemotherapy
lsoniazid plus PAS
S patients R patients
lsoniazid alone
S patients R patients
Total
90 8 9 6 0 (0)c 225 4 2 14 0 (0)
81 63 78 6 1 (17) 215 114 53 13 4 (31)
85 75 88 6 2 (33) 212 124 58 14 3 (21)
83 77 93 6 2 (33) 210 123 59 14 4 (29)
82 74 90 6 2 (33) 210 128 61 14 3 (21)
a Patients who died of non-tuberculous conditions are excluded after their death and patients who had their chemotherapy
charmed en account of toxicity are excluded after the change; tuberculous deaths and patients who had their chemotherapy  changed
owing to deterioration remain-in the totals throughout.
b Even if the smear was positive.
c The parentheses indicate percentages based on fewer than 25 observations.
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Sputum culture results
Table 8 shows the number of patients with
negative cultures on admission to treatment and at
three, six, nine and 12 months after the start of
chemotherapy based on single collection (overnight)
specimens. At three months, 78% of 81 S patients
and 17% of six R patients on isoniazid plus PAS
yielded a negative culture. The corresponding
proportions at six months were 88% and 33%,
respectively, and there was little change at nine and
12 months. At three months, 53 % of 215 S patients
and 31% of 13 R patients on isoniazid alone yielded
a negative culture. The proportions at six months
were 58 % and 21%, respectively, and there was little
change subsequently.
Fig. 1 and Fig. 2 show, for the combined and single
drug therapies respectively, the percentage of
patients all of whose multiple cultures (an average of
three) were negative at each monthly examination.
The graphs demonstrate the superior response of
the S patients, but also show that the bacteriological
response among the R patients was apparent from
the early months of treatment.
Response to treatment during the 12 months
Table 9 classifies the patients at the end of 12
months, mainly on the basis of their bacterio-
logical response to treatment. Favourable response
is (a) bacteriologically quiescent disease (all cultures,
FIG. 1
PERCENTAGE OF PATIENTS ON ISONIAZID PLUS PAS
WITH ALL CULTURES NEGATIVE AT EACH MONTH
FIG. 2
PERCENTAGE OF PATIENTS ON ISONIAZID ALONE
WITH ALL CULTURES NEGATIVE AT EACH MONTH
usually numbering 7-9, negative for at least the last
three monthly examinations, that is, at 10, 11 and
12 months) or (b) disease of doubtful bacteriological
status (one positive culture at one of the last three
monthly examinations following at least three months
of culture-negativity). Unfavourable response is (a)
relapsed disease (bacteriologically positive on at
least two occasions in the last three months following
negative results for all the cultures at three or more
consecutive monthly examinations), (b) bacterio-
logically active disease (no period of three con-
secutive months of culture-negativity, or change of
chemotherapy due to radiographic or serious clinical
deterioration) or (c) death from tuberculosis.
Only eight (9%) of 86 S patients on isoniazid
plus PAS had an unfavourable response, as compared
with five (83%) of six R patients, a statistically
highly significant difference (P <0.001); four of the R
patients had bacteriologically active disease and the
fifth had deteriorated radiographically and the
chemotherapy had been changed. Of 216 S patients
on isoniazid alone, 93 (43 %) had an unfavourable
response, as compared with 12 (86%) of 14 R
patients, also a highly significant difference (P <0.01);
eight of the 12 had active disease, one had relapsed
disease, two had had their chemotherapy changed
following a radiographic deterioration and one had
died of tuberculosis.
The course of the disease in the R patients during
the second year is considered on page 822.
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TABLE 9
CLASSIFICATION OF THE PATIENTS AT THE END OF 12 MONTHS ACCORDING
TO THEIR RESPONSE TO TREATMENT
Response
lsoniazid plus PAS
S patients R patients
No. % No. %
lsoniazid alone
S patients R patients
No. % No. %
Favourable a
Unfavourable
Total
78
8
86c
91 1 (17)b 123 57 2 (14)
9 5 (83) 93 43 12 (86)
100 6 100 216d 100 14 100
a Defined as bacteriologically quiescent disease or disease of doubtful status bacteriologically
(page 815).
b The parentheses indicate percentages based on fewer than 25 observations.
c Excluding two patients who died of non-tuberculous conditions and two patients who had their
chemotherapy changed on account of toxicity.
d Excluding three patients who died of non-tuberculous conditions and six patients who had their
chemotherapy changed on account of toxicity.
OTHER FACTORS WHICH MIGHT INFLUENCE
THE COMPARISON OF THE S AND THE R PATIENTS
Analyses were undertaken to. see whether the S
and the R patients were similar in terms of their
physical activity during the 12 months and in the
regularity of their self-administration of the medicine.
It will be appreciated that if the S patients had had
much greater physical activity than the R patients or
had been more irregular in the self-administration
of their medicine, this might have given an advantage
to the R patients unrelated to the effectiveness of the
chemotherapy.
Physical activity
There were only minor differences in the physical
activity of the S and the R patients during the
12 months of treatment. By the end of this period 80
(93%) of 86 S patients on isoniazid plus PAS had
returned to part-time or full-time activity, as com-
pared with five (83%) of six R patients. The cor-
responding proportions for the patients on isoniazid
alone were 162 (75 %) of 216 S patients and nine
(64%) of 14 R patients.
Regularity in self-administration of the medicine
One of the methods used to determine whether
the patients were taking the medicament regularly
was to test the urine for the presence of PAS in
patients on isoniazid plus PAS (Simpson, 1956)
and for isoniazid in patients on that drug alone
(Gangadharam et al., 1958) at their weekly visit to
the Centre. Of the 86 S patients on isoniazid plus
PAS, there were 31% who yielded only positive
results, as compared with 33 % of the six R patients
on the combined chemotherapy. Of 214 S patients
on isoniazid alone, 30 % yielded only positive results,
as compared with 57% of the 14 R patients.
The 86 S patients on isoniazid plus PAS had a
total of 4092 urine tests performed during the year
at their weekly visits of which 4.8% were negative,
as compared with 5.2% of 290 such tests in the six R
patients. The corresponding proportions for the
patients on isoniazid alone were 6.0% of 9643 teats
in 214 S patients and 1.4% of 589 tests in the 14 R
patients. These findings therefore suggest that the
drugs were being taken with considerable regularity
throughout the 12 months and that the R patients
on isoniazid alone were more regular than the
corresponding S patients.
RESPONSE OF THE R PATIENTS IN THE FIRST
THREE MONTHS
It is possible that the clinical improvement
observed in the R patients might conceivably
represent a benign natural history of the disease and
be unrelated to the chemotherapy. The progress of
the R patients in the first three months of treatment
has, therefore, been studied in detail in order to
discover whether or not the responses coincided with
the commencement of chemotherapy.
Weight changes
The mean weight gain of the six R patients on
isoniazid  plus PAS was 6.2 1b.by one month, 9.2
1b.  by two months, 10.3 1b. by three months and
9.2 1b. by six months.  For the R patients on isoniazid
alone, the corresponding figures were 1.7 1b., 3.8
1b., 5.3 1b. and 7.7 1b.  There was, thus, an
association between gain in weight and the start of
treatment, the patients having gained more weight
in the first than in the second three months.
Erythrocyte sedimentation rate
All the six R patients on isoniazid plus PAS had
elevated ESRs (more than 10 mm) at the
commencement of treatment and all had lower
values at three months.  Similarly, of the correspon-
ding 14 R patients on isoniazid alone, 12 had lower
values at three months.
Radiographic changes
At an independent assessment, all six R patients
on isoniazid plus PAS showed radiographic
improvement in the first three months.  In four the
improvement was moderate and in the remaining
two it was slight.  Of the 14 R patients on isoniazid
alone, 11 showed radiographic improvement in the
first three months.  In one of the improvement was
considerable and in the other 10 it was slight.  Of
the remaining three patients, one showed no
improvement, one moderate deterioration and one
died of tuberculosis.
The assessor apportioned, between the first and
the second three months, the over-all radiographic
change observed in the first six months.  Greater
improvement occurred in the first three months in
all the six patients on isoniazid plus PAS.
Considering the 14 patients on isoniazid alone,
greater improvement occurred in the first three
months in five and in the second three months in
two, and there was equal improvement in the two
periods in five.  One patient died in the first three
months and one patient had his chemotherapy
changed on account of radiographic deterioration
in the second three months.  Thus, there was
evidence that the earlier period after the start of
chemotherapy was the period of greater radiographic
improvement for the patients on isoniazid plus PAS.
For the patients on isoniazid alone it was usually
the period of greater or equal improvement.
Changes in cavitation
At an independent assessment, one patient on
isoniazid plus PAS had no residual cavitation, four
had less and in one it was unchanged at the end of
three months’ treatment.  Of the 12 patients with
initial cavitation on isoniazid alone, the cavitation
had disappeared in one by three months, was less in
six, was unchanged in two and more in two, and
one patient had died of tuberculosis.
The assessor apportioned the changes observed
in the first six months between the first and the
second three months.  Five of the six patients on
isoniazid plus PAS showed more improvement in
the first three months and the sixth showed equal
changes both periods.  For the isoniazid-alone series,
of 12 patients assessed, six showed greater
improvement in the first three months, one showed
equal improvement in both periods, one showed
greater improvement in the second three months and
four showed no change in either period.  It may be
concluded that both for the combined chemotherapy
and for the isoniazid-alone series, there was evidence
of greater improvement in cavitation in the first than
in the second three months.
Sputum culture results
It may be seen from Fig.1 and 2 that there was a
bacteriological response in the first three months
both for the combined chemotherapy and for the
isoniazid-alone series.  All the four patients (one
receiving isoniazid plus PAS and three isoniazid
alone) who attained quiescence and six (four
receiving isoniazid plus PAS and two isoniazid
alone) who showed a fall in the bacterial content of
the sputum, followed by a rise, demonstrated a clear
benefit bacteriologically in the first three months.
In summary, the R patients demonstrated
response by sever different criteria in the first three
months of treatment and it seems likely that these
were due to the effect of chemotherapy, as nearly
all the patients had advanced disease, were clinically
ill on admission to treatment and, in addition, ha
little bed rest as they were all treated at home under
ambulatory conditions.
RANKING OF THEIR PATIENTS
The 20 R patients were ranked according to their
progress in the 12-month period (Table 10).  In the
ranking, primary consideration was given to
bacteriological response.  Among those who shoed
a similar bacteriological response the ranking was
based on the over-all radiographic progress and
changes in the cavitation.  If these were equal
the higher rankings were give to  patients with the
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TABLE IO. RANKING OF THE R PATIENTS ACCORDING TO THEIR RESPONSE TO TREATMENT
e
in the
Treatment a
Bacterio-
logical
125 1 HI-2 Quiescent
247 2 PH Quiescent
294 3 HI-2 Quiescent
212 4 H Relapsed
6 5 PH Fall and rise
189 6 PH Fall and rise
187 7 PH Fall and rise
82 8 HI-2 Fall and rise
104 S HI-I Fall and rise
174 10 PH Fall and rise
145 11 HI-1 None
158 12 H None
296 13 HI-2 None
12 14 H None
190 15 HI-2 None
2 16 HI-2 None
244 17 PH None
225
236
84
18 None
19 None
20 None
Response In the 12-month period
Radio-
graphic b
Change
in cavitation
4 +
4+
3 +
3+
2 +
2+
2+
1+
1+
0
3+
2+
2+
2+
  2+
2+
Disappeared +14
Disappeared + 9
Less + 9
Disappeared + 9
Disappeared + 8
Less +13
Less + 5
None throughout + 5
None throughout + 6
Less +14
Less +12
Less +19
Less + 8
Unchanged +17
Less +10
Less - 2
Tuberculous death
AND VARIOUS FACTORS ON
Age
(years)
25 Slight
23 Slight
18 Moderate
26 Moderate
29 Slight
20 Moderate
29 Extensive
24 Nil
27 Nil
18 Moderate
33 Moderate
33 Moderate
29 Moderate
37 Moderate
23 Moderate
28 Moderate
26 Moderate
47 Moderate
24 Moderate
13 Extensive 
a See page 808.
b 4+, 3+, 2+, 1+ and 0 indicate exceptional, considerable, moderate, slight and no improvement, respectively.
c 1 lb. = 0.45 kg.
d See page 810.
more extensive cavitation and the larger total
extent of disease on admission to treatment.
Table 10 shows the ranking at 12 months, in
relation to the treatment, the progress in the 12-
month period and various factors on admission to
treatment. It will be seen that the first 10 patients
showed a bacteriological response; four attained
quiescence, though one subsequently relapsed, and
six showed a clear fall in the bacterial content of the
sputum, as judged by the smear and culture results,
followed by a rise. The majority of the patients
showed radiographic improvement, disappearance
or a reduction in the size of cavitation and gains in
weight.
Prognostic value of various factors on admission to
treatment
It will be seen from Table 10 that there was no
association between response to treatment and the
age of the patients, the bacterial content of the
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IN THE 12-MONTH PERIOD, WITH TABULATIONS OF SOME MEASUREMENTS OF PROGRESS
ADMlSSlON TO TREATMENT
Total
extent
of disease
Moderate
Moderate
Extensive
Limited
Limited
Extensive
Extensive
Limited
Trivial
Mod&ate
Moderate
Moderate
Extensive
Moderate
Extensive
Moderate
Moderate
Moderate
Extensive
Gross
Bacterial
content
of sputum a
1-plus
2-plus
3-plus
2-plus
2-plus
2-plus
3-plus
P-PIUS
Negative
2-plus
3-plus
1-plus
3-plus
2-plus
3-plus
2-plus
3-plus
Negative
3-plus
2-plus
Factors on admission to treatment
Highest isoniazid
concentration
allowing equal
growth on first and
second cultures
(µg/ml) e
1, 1
1, 5
1, 1
> 5, 0.2
0.2, 50
1, 1
50, 50
5, 1
0.2, 50
1, 5
>50, >50
5, 5
5,         5         
5, 5
1, 1
50, >50
5, 5
5, 5
1, 1
1, 1
0.2
<0.2
0.2
<0.2
<0.2
0.2
0.2
<0.2
<0.2
<0.2
5
<0.2
1
0.2
<0.2
0.2
1
1
0.2
<0.2
<0.2
<0.2
<0.2
<0.2
<0.2
0.2
1
0.2
<0.2
<0.2
50
1
1
0.2
0.2
0.2
<0.2
1
0.2
0.2
80, 90
70, 80
80, 2+
60, 2+
2+, 80
90, 2+
30, 40
50, 50
2+, –
70, 80
30, 20
30, 30
60, 80
20, 90
80, 2+
90, 90
90, 90
80, 90
60, 60
20, 30
Virulence in the
guinea-pig
T
Culture
i n j e c t e d
First
Second
Second
Second
Second
First
–-
Second
First
First
Second
Second
Second
First
Second
Second
Second
First
Root-index
of virulence g
Rate of
inactivation
of
isoniazid
0.53 Slow
1.12 Slow
0.58 Slow
0.57 Slow
0.68 Rapid
0.95 Rapid
–- Slow
0.51 Slow
–- Slow
0.70 Rapid
0.64 Slow
0.55 Slow
0.88 Slow
1.24 Slow
0.74 Rapid
0.54 Slow
0.52 Slow
0.56
0.56
0.59
Slow
e Growth equal to that on the drug-free slope.
f Result of the semi-quantitative test expressed as a percentage and, when this was not available, that of the
qualitative test: a dash indicates no result available.
g The root-indices obtained in the Madras series ware adjusted to those in the Porton series, as described
by Mitchison et al. (1961).
sputum, the catalase activity or the virulence in with all 10 patients who did not show such a response.
the guinea-pig of the pretreatment cultures. Only Similarly, the total extent of the disease was classified
four of 18 patients tested were rapid inactivators of as at least moderate in six of the former patients,
isoniazid, but three of them demonstrated a bacterio- as compared with all 10 of the latter.
logical response. There was, however, some associa- Of the three patients who had one sensitive and
tion between the extent of cavitation and the total one resistant culture before treatment, one attained
extent of the disease initially and the response to bacteriological quiescence but then relapsed and the
treatment. Thus of the 10 R patients who showed other two had a fall in the bacterial content of the
some bacteriological response, only five had mode sputum followed by a rise (these patients were
rate or extensive cavitation initially, as compared ranked 4, 5 and 9, respectively). For two of the
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three patients who had quiescent disease at 12 months
both cultures had low levels of resistance (MIC of
1 µg/ml). On the other hand, the patient who died
and one of the patients who deteriorated and had his
chemotherapy changed (ranked 20 and 19, respect-
ively) also had similar strains. Even so there is a
suggestion that the patients with the highest ranking
had lower MICs than the patients lower in the
ranking. There seemed to be a strong& suggestion
of an association between the response to treatment
and the highest concentration of isoniazid which
allowed growth equal to that on the drug-free control
slope. Thus, only one of six patients who had one
or more cultures which yielded equal growth on
1 µg/ml isoniazid or more showed a bacteriological
response, as compared with nine of 14 patients with
equal growth on 0.2 µg/ml isoniazid or less. How-
ever, all six patients whose cultures yielded equal
growth on 1 µg/ml isoniazid or more had moderate
or extensive cavitation initially, as compared with
nine of the 14 patients with lower levels of resistance
by this definition.
Response to treatment
Five of the six patients on isoniazid plus PAS,
as compared with five of the 14 patients on isoniazid
alone, showed a bacteriological response. Con-
sidering the patients on isoniazid alone further, four
of eight patients on a moderate dosage of the drug
(HI-1 and HI-2 regimens), as compared with only
one of six patients on a low dosage (H regimen),
showed a bacteriological response. However, the
patients on the moderate dosage of isoniazid alone
were at an advantage on admission to treatment in
comparison with those on the low dosage of the
drug. Thus, only five of the eight HI-1 and HI-2
patients had moderate or extensive cavitation, as
compared with all six of the H patients.
Heterogeneity of the isoniazid-resistant cultures
Evidence of the presence of a component of
isoniazid-sensitive organisms in the bacterial popula-
tions harboured by the R patients on admission to
treatment was obtained from four methods: (1) by
the finding that one of the two cultures before
treatment was sensitive to isoniazid; (2) by the
occurrence in the isoniazid-sensitivity test of greater
growth on the drug-free control slope than on
the slope containing 0.2 µg/ml isoniazid–a finding
which suggests that sensitive organisms were
being inhibited by isoniazid; (3) by the occurrence.
in the isoniazid-sensitivity test of greater catalase
activity on the drug-free control slope than on the
slope containing 0.2 µg/ml isoniazid; and (4) by
the recovery of isoniazid-sensitive cultures from the
spleens of guinea-pigs infected with the isoniazid-
resistant cultures. Table 11 shows the number of R
patients who appeared to have harboured isoniazid-
TABLE 11
PRESENCE OF A COMPONENT OF ISONIAZID-SENSITIVE TUBERCLE BACILLI IN PATIENTS WITH ISONIAZID-
RESISTANT CULTURES ON ADMISSION TO TREATMENT
Evidence for the presence
of isoniazid-sensitive tubercle bacilli
Number
of patients
tested
Evidence of a
Number of bacteriological response
patients with Fall in Ranking accordinga component
of isoniazid the bacterial
to response
sensitive- Quiescence content of
in the 12-month period
organisms at 12 months the sputum
(see Table 10)
followed by
a rise
1. One culture sensitive and the other
resistant to isoniazid
2. Less growth on 0.2 µg/ml slope
than on drug-free slope  19  3  2  8  2,3,4,5,10,15,17,20
3. s e  
 19  7  1  3 2,5,6,8,11,12,16
4. Recovery of isoniazid-sensitive cul-
tures from spleens of guinea-pigs 8 5 0 2 5, 10, 14, 11, 18
sensitive organisms according to these four methods
of assessment and their response to treatment.
According to method 1, three of the 20 patients were
excreting isoniazid-sensitive organisms on
admission treatment.  The corresponding figures for
method 2 were eight of 19 tested, for method 3,
seven of 19 tested, and for method 4, five of eight
tested.  In all, 16 of the 20 patients gave evidence
by one or more of the four criteria of having had an
isoniazid-sensitive component on admission to
treatment.  It will be observed, however, that there
was very little agreement between the methods
(Table 11).  Moreover, only about half the patients
with evidence of isoniazid-sensitive tubercle bacilli
obtained by any one of the four methods showed a
bacteriological response.  On the other hand, of the
five patients (ranked 2,4,5,10 and 17) who were
shown to have a component of sensitive organisms
by at least two methods, four showed a bacteriolo-
gical response.
LEVEL OF ISONIAZID-RESISTANCE OF THE
CULTURES FROM THE R PATIENTS BEFORE AND
DURING TREATMENT
The levels of isoniazid-resistance of the two
cultures before the start of treatment and the levels
for  single cultures at the end of three, six, nine and
12 months of the allocated chemotherapy are
presented in Table 12.  In comparison with the first
pretreatment culture, the level of resistance at 12
months was lower in three, the same in four and
higher in six.  In comparison with the second
pretreatment culture, the level of resistance at 12
months was lower in four, the same in three and
higher in six.  Results were not available for three
patients who were bacteriologically negative at 12
months, three more patients had had their
chemotherapy changed and one had died.  There
was thus a slight tendency for an increase in the
degree of isoniazid-resistance of the cultures isolated
from patients at the end of 12 months of
chemotherapy.  A similar trend was also apparent
when the cultures at three, six and nine months were
compared with the pretreatment cultures.
CATALASE ACTIVITY OF THE CULTURES FROM THE
R PATIENTS BEFORE AND DURING TREATMENT
Table 13 presents the catalase activity of the two
cultures from the R patients before the start of
treatment and those of single cultures at the end of
three, six, nine and 12 months of the allocated
chemotherapy.  The results of the semi-quantitative
test and, if these were not available, the results of
the qualitative test, are given.  In comparison with
the results of the semi-quantitative tests on the first
pretreatment culture, the catalase activity at 12
months was lower in seven and higher in four (results
either before treatment or at 12 months were not
available in nine case).  Considering the second
pretreatment culture, the catalase activity at 12
months was less in the eight, the same in one and
more in none (results either before treatment or at
12 months were not available in 11 cases).  There
was, therefore, evidence of lower catalase activity
of the cultures isolated from patients at the end of
12 months’ chemotherapy in comparison with the
pretreatment cultures.  Further analysis revealed that
this was also apparent in the cultures from the
patients at six and at nine months, although not at
three months.
In summary, there was a tendency for an increase
in the degree of isoniazid-resistance of the cultures
and a decrease in their catalase activity to occur
during treatment.
CLASSIFICATION OF THE PATIENTS BY OTHER
DEFINITIONS OF RESISTANCE
There are a number of definition of isoniazid-
resistance in common use, some of which are quoted
by Canetti (1957).  Apart from the definition in use
in the Tuberculosis Chemotherapy Centre, other
main definitions include:
(a) Equal growth in the control tube and 1 ug/ml
isoniazid tube, or any growth on 5 ug/ml isoniazid
(Chaves et al., 1955, 1956; United States Veterans
Administration, 1959).
(b) Growth on the 1 mg/ml tube equal to that of
the control tube (quoted by Canetti, 1957).  (This
definition is still widely used on the Continent of
Europe (Canetti, personal communication, 1960).)
None of the S patients in the present study would
have been classified as harbouring resistant
organisms by either of the above two definitions.
The 20 R patients have been reclassified
according to these two definitions (Table 14).  The
United States Veterans Administration definition
would have classified the cultures from eight of the
20 patients as isoniazid-sensitive.  Five of these eight
patients had an unfavourable response to treatment.
The definition quoted by Canetti (1957) would have
classified the cultures from 13 of the patients as
isoniazid-sensitive. Of these 13, 10had an
unfavourable response to treatment, However, all
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TABLE 12
DEGREE OF ISONIAZID-RESISTANCE OF THE CULTURES ISOLATED FROM
THE PATIENTS BEFORE TREATMENT AND AT THE END OF THREE, SIX, NINE
AND 12 MONTHS OF CHEMOTHERAPY (MIC OF ISONIAZID IN µg/ml)
Regimen
PH
HI-I
HI-2
H
6
174
187
189
244
247
104
145
2
82
125
190
294
296
12
84
158
212
225
236
Months after start of chemotherapy
0
1st 2nd
culture culture
0.2 50
1 5
50 50
1 1
5 5
1 5
0.2 50
>50 >50
50 >50
5 1
1 1
1 1
1 1
5 5
5 5
1 1
5 5
> 5 0.2
5 5
1 1
a Result of a culture at 11 months.
b Result of a culture at five months.
3 6 9
–
5
5
1
>50
1
>50
50
Culture
negative
5
5
50
50
Culture
negative
>50
>50
5
Culture
negative
>50
>50
5
Culture
negative
>50
>50
5
5
Culture
negative
>50
Culture
negative
5
5
>50
Culture
negative
>50
Culture
negative
5
5
>50
Culture
negative
50
Culture
negative
5
1
Died
5
5
5
5
5
–
5
5 b
5
5
–
5
Culture
negative
Change of chemotherapy
Change of chemotherapy
three patients who had quiescent disease at 12 months
would have been classified as having isoniazid-
sensitive infections by both these definitions.
Another definition of isoniazid-resistance (Russell
& Dye, 1957; Middlebrook et al., 1960) classifies
cultures as resistant to isoniazid if 1% of the bacilli
are resistant to 0.2 µg/ml isoniazid. By using a
criterion which considers confluent growth as
representing the growth of approximately 1% or more
of the total organisms inoculated, both the cultures
from each of five of the 20 R patients would be
12
>50 a
1
5
50
Change of
chemotherapy
Culture
negative
50
5
5
>50
Culture
negative
5
Culture
negative
5
50
–
5
5 a
classified as isoniazid-sensitive. (Seven patients
would have one culture classified as sensitive and the
other as resistant and eight patients as both cultures
resistant.) Of the five patients with both cultures
classified as sensitive (ranked 2, 4, 5, 9 and 10), four
had an unfavourable response.
PROGRESS OF THE R PATIENTS IN THE SECOND YEAR
Of the three patients (one on isoniazid plus PAS,
two on isoniazid alone) who had quiescent disease
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TABLE 13
CATALASE ACTIVITY OF THE CULTURES ISOLATED FROM PATIENTS BEFORE
TREATMENT AND AT THE END OF THREE, SIX, NINE AND 12 MONTHS
OF CHEMOTHERAPY a
Regimen
PH
HI-1
HI-2
H
0
1st 2nd
culture culture
3 6 9 12
6
174
187
189
244
247
2+ 80
70 80
30 40
90 2+
90 90
70 80
2+ –
30 20
–
100
10
90
70
Culture
negative
104
145
0
40
2 90 90
82 60 50
125 80 90
190 80 2+
294 80 2+
296 60 80
40
30
Culture
negative
80
Culture
negative
70
12 20 90 30
84 20 30 Died
158 30 30 50
212 60 2+ 80
225 80 90 80
236 60 60 70
Months after start of chemotherapy
10
70
30
50
80
Culture
negative
10
0
70
30
Culture
negative
40
Culture
negative
60
90
–
10
80c
90
Culture
negative
50
50
70
80
Culture
negative
10
0
50
20
Culture
negative
80
Culture
negative
100
90
–
20
Culture
negative
0 b
30
10
100
Change of
chemotherapy
Culture
negative
0
0
70
20
Culture
negative
90
Culture
negative
80
60
–
10
50 b
Change of chemotherapy
Change of chemotherapy
a Result of the semi-quantitative test expressed as a percentage, but for a few of the pretreat-
ment cultures, where this was not available, that of the qualitative test.
b Result of a culture at 11 months.
c Result of a culture at five months.
at 12 months, two received 200 mg of isoniazid daily PAS (ranked 7 and 10) deteriorated radiographically
and the third a placebo (calcium gluconate) in the in the sixteenth and seventeenth months, respectively,
second year. None of these three patients relapsed. and three on isoniazid alone (ranked 14, 15 and 16)
All the 13 patients with active disease at 12 months deteriorated in the thirteenth, eighteenth and nine
who were still on the originally prescribed chemo- teenth months, respectively, to an extent which
therapy continued on it in the second year. One on necessitated a change of chemotherapy. In view of this
isoniazid plus PAS (ranked 5) became bacterio- high incidence of deterioration, the treatment of the
logically quiescent from the fourteenth month. Of remaining seven patients (one on isoniazid plus PAS
the remaining 12 patients two on isoniazid plus and six on isoniazid alone), all of whom were excre-
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TABLE 14
COMPARISON OF DIFFERENT DEFINITIONS OF lSONlAZlD-RESlSTANCE
AND UNFAVOURABLE RESPONSE TO TREATMENT
Definition of isoniazid
resistance
Growth on 1 µg/ml isoniazid
slope equivalent to that on the
control slope, or any growth on
5 µg/ml slope (Chaves et al.,
1955, 1958; United States Vete-
rans Administration, 1969)
Growth on 1 µg/ml isoniazid
slops equivalent to that on the
Definition used in the
present study (see page 809)
Results of 2
pretreatment
isoniazid-
sensitivity
tests
Both
sensitive
 resistant
Both
resistant
Both
sensitive
Both
resistant
Both
resistant
- -
8
Unfavourable
response a
5
5
7
10
4
3
3
14
Ranking according
to response
in the 12-month
period
(see Table 10)
1, 2, 3, 6, 14, 15, 19,
20
4, 5, 8, 9, 17
12, 13, 16,
1, 2, 3, 4, 5, 6, 8, 10,
14, 15, 16, 19, 20
7, 9, 12, 17
11, 13, I8
4, 5, 9
1, 2, 3, 6, 7, 8, 10, 11,
12, 13, 14, 15, 16, 17,
18, 19, 20
a Defined as bacteriologically relapsed disease, bacteriologically active disease or death from
tuberculosis (see gage 815).
ting tubercle bacilli, was changed in the thirteenth, six-
teenth, seventeenth, nineteenth, nineteenth, twentieth
and twenty-first months of treatment, respectively.
In summary, of the six patients on isoniazid plus
PAS, two attained quiescence and three deteriorated
radiographically necessitating a change of chemo-
therapy in the 2-year period. Of the 14 patients on
isoniazid alone, two attained quiescence, five dete-
riorated radiographically necessitating a change of
chemotherapy and one died of tuberculosis in the
2-year period. The remaining seven patients had
active disease and had their chemotherapy changed
in the second year. This observation is similar to the
finding that the considerable majority of the S
patients with bacteriologically active or relapsed
disease at 12 months deteriorated radiographically
or continued to excrete tubercle bacilli in the second
year (Ramakrishnan et al., 1962).
DISCUSSION
There have been several reports on the prevalence what different population, a prevalence of 0.8%
of infection with isoniazid-resistant organisms in New York City in 1955. Fox et al. (1957) reported
amongst untreated tuberculosis patients in chest a prevalence of 0.7% in Great Britain in 1955-56
clinic practice. Chaves et al. (1955) reported a and Bell & Brown (1960) a prevalence of 9.1%
prevalence of 2.3% of “ significant ” isoniazid- in Ashanti, Ghana, in 1958. A prevalence of
resistance in New York City between 1953 and 1955, 3.6% was found in 1956-57 in patients living in
and these authors (1956) also reported, in a some- Madras City (Tuberculosis Chemotherapy Centre,
1959) and, in the present study, the prevalence
in1957-58 was 5.9% (20 examples in 338 patients).
The survey reported by Fox et al. (1957) was a
national survey and is the only one based on a
representative sample of chest clinics chosen by a
random procedure.  It is difficult to compare the
above prevalence figures of drug-resistance because
of differences in the methods of performing
sensitivity tests and in interpreting the results
(Canetti, 1957; Rist & Crofton, 1960).  The two
studies in Madras between 1956 and 1958 showed
a considerably higher prevalence than that in Great
Britain in 1955-56 (Fox et al., 1957), in which a
very similar method of sensitivity testing and very
similar criteria for isoniazid-resistance were used.
There is little doubt that isoniazid alone has been
more widely used in Madras than in Great Britain
and this could explain the difference.  There is no
reason to think that the Madras figures include
patients who had acquired drug-resistance as a result
of chemotherapy for great care was taken to
investigate whether the patients had ever received
previous chemotherapy, and inquiries were made
not only during the first year of patients’ treatment,
but also subsequently.  Further, identification tests
were undertaken in all 20 patients’ (in detail in 18)
and those showed that the infecting organism was
Myco.tuberculosis var.hominis, so that the possibi-
lity of the infections being due to acid-fast organisms
other than tubercle bacilli has also been excluded.
In the present study, a comparison was made of
the disease status at the treatment in the 20 patients
with isoniazid-resistant strains and the 315 patients
with sensitive strains.  There was hardly any
difference in terms of  the extent of the  radiographic
lesion, the presence, or the extent of cavitation or
the bacterial content of the sputum.  There were,
however, major differences between them in the age
and sex distributions.  Thus, 18 of the 20 patients
with primarily isoniazid-resistant strains were males,
as compared with 199 (63%) of the 315 patients with
isoniazid-sensitive strains, a statistically significant
difference (P=0.01).  Further, 17 (85%) of the 20
patients with resistant organisms were under 35
years of age, as compared with 198 (63%) of the
315 patients with sensitive organisms, a statistically
significant difference (P-0.03).  These findings may
be compared with those of the earlier study
(Tuberculosis Chemotherapy Centre, 1959) in which
four of the seven patients who had primarily
isoniazid-resistant infections were males, three of
them being under the age of 35 years.  Amalga-
mating the findings for the two studies, there were
22 (81%) males amongst 27 patients infected with
isoniazid-resistant tubercle bacilli, as compared with
298 (62%) males amongst 487 patients infected with
sensitive organisms.  This difference attains statis-
tical significance (P-0.03). Of the 27 patients infec-
ted with isoniazid-resistant organisms, 22 (81%)
were under the age of 35 years, as compared with
304 (64%) of 478 patients infected with sensitive
ones, a statistically significant differences (P-0.04).
A comparison was made between patients
infected with organisms resistant to streptomycin
or isoniazid or both with those infected with strains
sensitive to both these drugs in the tow studies
combined.  It was found that of the 37 patients
infected with resistant strains 29 (78%) were males,
as compared with 304 (64%) of 477 patients with
sensitive strains.  Of the 37 patients infected with
resistant strains 28 (76%) were under the age of 35
years, as compared with 302 (63%) of the 477
patients with sensitive strains.  These differences
do not attain statistical significance and are smaller
than the corresponding differences encountered
when isoniazid-sensitivity alone was considered,
though they are in the same direction.  Thus there
was a suggestion that primarily isoniazid-and
streptomycin-resistant organisms were more
frequently found among male patients and among
patients under the age of 35 years.  These findings
may be compared with those from Great Britain,
where Fox et al. (1957) reported a higher prevalence
of resistance to isoniazid, streptomycin or PAS in
young women in comparison with the rest of their
population of tuberculous patients.
In the present study, only three of the 20 patients
with isoniazid-resistant infections had bacterio-
logically quiescent disease at one year-namely, one
of six patients who received isoniazid plus PAS and
two of 14 on isoniazid alone.  The inferiority of the
bacteriological response, both the patients on
isoniazid plus PAS and of those on isoniazid alone,
in comparison with the response of the patients with
sensitive organisms receiving the same treatment
attains statistical significance.  Despite the clear-cut
disadvantage in terms of the attainment of
bacteriological quiescence, there was evidence of
some bacteriological response in 10 patients, five
of whom received isoniazid plus PAS and five
isoniazid alone.  Moreover, the majority of patients
infected with isoniazid-resistant organisms showed
radiographic improvement, including reduction in
cavitation, had lower ESRs and gained weight.
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Thus, over the 12-month period radiographic
improvement was reported by an independent
observer in 15 of the 20 patients.  In five of them it
was assessed as exceptional or considerable.  The
independent observer also reported that, of 18
patients with cavitated lesions initially, cavitation
had disappeared in four and had become less in nine.
Moreover, 15 of the 20 patients gained weight, four
of them as much as 14 1b. or more.  In all these
assessments the progress approximated to that of
the patients infected with sensitive organisms.
In the earlier study (Tuberculosis Chemotherapy
Centre, 1959), of the six patients infected with
isoniazid-resistant tubercle bacilli who were treated
with isoniazid plus PAS whose response to therapy
could be assessed, three attained bacteriological
quiescence, four showed radiographic improvement
which included the disappearance or reduction of
the cavitation and five gained weight when assessed
at the end of 12 months of chemotherapy.
Amalgamating the findings for the two studies, of
the 12 patients infected with isoniazid-resistant
organisms who were treated with isoniazid plus PAS,
four attained bacteriologically quiescent disease, as
compared with 218 (87%) of 249 patients infected
with sensitive organisms. This difference attains
statistical significance (P<0.001).
Thibier et al. (1960) treated two patients, infected
with isoniazid-resistant tubercle bacilli, with isonia-
zid plus PAS. One of them received this combination
for over a year and the other for four-and-a-half
months, after which period streptomycin was added.
Both patients showed definite radiographic
improvement by three months and both had negative
cultures by the end of the first month of treatment.
The authors, however, point out that these two
patients authors, however, point out that these two
patients had limited non-cavitated disease initially,
with scanty expectoration of tubercle bacilli.
It is of interest to consider the various reasons
why these patients infected with isoniazid-resistant
tubercle bacilli in our study demonstrated response
during the 12 months. They may have responded
(a) because the natural history of untreated
pulmonary tuberculosis in the Madras Patients,
whether the tubercle bacilli are isoniazid-sensitive
or isoniazid-resistant, follows a benign and
improving course, or (b) because the infecting
isoniazid-resistant organisms were attenuated to the
patients and the disease in them was therefore
spontaneously follo-wing an improving course, or
(c)as a direct conse-quence of the chemotherapy,
whether isoniazid plus PAS or isoniazid alone.
The first two are unlikely explanations as nearly
all the patients had advanced disease and were
clinically ill on admission to treatment, and all were
treated at home under ambulatory conditions in an
overcrowded environment. For example, 18 of the
20 patients had cavitated lesions on admission to
treatment. Moreover, there was no difference in the
virulence in the guinea-pig of the cultures from the
patients infected with isoniazid-resistant strains in
comparison with those from patients infected with
sensitive strains, although the catalase activity of
the former was found to be less on the average.
Thibier et al. (1960) reported that seven of their 14
patients infected with isoniazid-resistant tubercle
bacilli had cavitated lesions and thus found evidence
that these organisms were producing major lesions
in their patients.
There is some evidence in favour of the third
explanation. First, the response was most marked
in the early months, suggesting a direct association
with the administration of the chemotherapy.
Secondly, the type of chemotherapy appeared to
influence the response. Thus, five of six patients on
isoniazid plus PAS, as compared with five of 14
patients on isoniazid alone, demonstrated a
bacteriological response. It is therefore likely that
PAS made a contribution to the improvement in the
patients on the combination.
The following further reasons may be put for-
ward to explain why these patients infected with iso-
niazid-resistant organisms responded to treatment:
1. Three of the 20 patients were known, from
the results of the sensitivity tests, to be excreting a
mixture of isoniazid-sensitive and isoniazid-resistant
organisms, and there was other evidence which
suggested that 13 of the remaining 17 patients were
also excreting a mixture of sensitive and resistant
organisms. The sensitive organisms would be
expected to respond to isoniazid.
2.  There was a suggestion that patients excreting
organisms with low levels of resistance to isoniazid
before treatment responded better, on the average,
than those excreting organisms with high levels of
resistance. Also there was a tendency for the degree
of isoniazid-resistance of the cultures to increase
during treatment. Both these observations suggest
that the strains with low levels of resistance were
inhibited by the isoniazid.
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3.  The possibility must be considered that the
isoniazid-sensitivity tests in the Centre are techni-
cally unreliable and that patients were classified as
having resistant strains when the organisms were,
in fact, sensitive. However, there is evidence that
the isoniazid-sensitivity tests in the Centre are highly
reproducible. A sample of 63 cultures (10 sensitive
and 53 resistant to isoniazid), isolated from patients
in the chemotherapy study before the start of
treatment and at intervals up to the twenty-fourth
month of treatment, was tested on two occasions.
The pairs of tests were set up and read by separate
workers. Of the 63 pairs, 56 had the same minimal
inhibitory concentration in both tests. The other
seven differed only one dilution step, and none of
these yielded a sensitive result in one test and a
resistant result in the other.
Caneti (1957) classified, according to eight
different criteria of resistance (four of them in wide
use at the time), 113 strains of tubercle bacilli
isolated from pulmonary lesions after “various forms
of treatment” with isoniazid. The proportion of
resistant cultures ranged from 24% to 99%, the latter
figure applying to the Medical Research Council’s
definition, which is very similar to that used in the
present report. The 20 patients in the present study
SUMMARY
1. Twenty (5.9%) patients excreting isoniazid-
resistant tubercle bacilli were encountered among
338 previously untreated patients with active
pulmonary tuberculosis who were admitted to a
chemotherapeutic study.
2. In this paper 315 of the patients infected with
isoniazid-sensitive tubercle bacilli (the S patients)
have been compared with the 20 patients infected
with resistant organisms (the R patients).  There was
little difference in terms of the extent of the
radiographic lesion, the extent of cavitation or the
bacterial content of the sputum before the start of
treatment.  There were, however, major differences
between them in the age and sex distributions, there
being a great preponderance of young males among
the R patients. Thus, of the 315 S patients, 199 (63%)
were males, as compared with 18 (90%) of the 20 R
patients, and of the 199 S males 113(57%) were less
than 35 years old, as compared with 15 (83%) of
the R males.
3. The catalse activity of the pretreatment
cultures from the S patients was, on the average,
grater than that of the cultures from the R patients,
but there was, on the average, no difference between
infected with isoniazid-resistant organisms
(according to this definition) were also classified
according to two other definitions of resistance—
namely, the one in use by the United States Veterans
Administration (1959) and a definition that is widely
used on the Continent of Europe (quoted by Canetti,
1957). Although these two definitions classified the
three patients who had quiescent disease at 12
months as having isoniazid-sensitive infections,
which is in keeping with the satisfactory
bacteriological response, both appeared to be less
successful than the definition used in the present
study in identifying patients infected with isoniazid-
resistant strains who are likely to fail to attain
bacteriological quiescence.
It may be concluded that this study has shown
that the treatment of patients infected with isoniazid-
resistant tubercle bacilli is unsatisfactory, whether
isoniazid is used alone or in combination with PAS,
and that only a small proportion of the patients will
attain bacteriological quiescence. Although they
frequently showed a good clinical and radiographic
response in the first year of treatment, the longer
course of the disease was towards serious
radiographic deterioration.
them in their virulence in the guinea-pig.
4. In all, 90 S patients and six R patients were
treated with isoniazid plus PAS, while 225 S patients
and 14 R patients received isoniazid alone in three
different dosage schedules.  The treatment was
allocated for a year.
5. By the end of 12 months of treatment eight
(9%) of 86 S patients on isoniazid plus PAS showed
an unfavourable bacteriological response, as
compared with five (83%) of the six R patients.
Correspondingly, 93 (43%) of 216 S patients on
isoniazid alone showed an infavourable response,
as compared with 12 (86%) of the 14 R patients.
The differences attain statistical significance in both
the treatment series.
6. When over-all radiographic progress, as
assessed by an independent observer, weight
changes and changes in ESR were considered, the
progress of the R patients in the first year
approximated to that of the S patients, but radio-
graphic deteriorations occurred subsequently.
7. Evidence has been adduced to show that the
response of the R patients was due to the chemo-
therapy.
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RÉSUMÉ
Parmi les 338 malades, jusqu’alors non traités, présen-
tant une tuberculose active, admis à participer à l’étude
chimiothérapique, on en a trouvé 20 (5,9%) qui élimi-
naient des bacilles résistants à l’isoniazide.
Dans cet article, les auteurs comparent 315 des malades
infectés par des bacilles sensibles à l’isoniazide (malades S)
avec les 20 malades infectés par des bacilles resistants
(malades R). Il y avait peu de differences entre eux,
avant le début du traitement, quant à l’étendue des
lesions révélées par la radiographie, à la grandeur des
cavités ou à la teneur en bacilles des crachats. Par contre,
il y avait entre eux de grandes différences dans la réparti-
tion par âge et sexe, car on trouvait une grande majorité
de jeunes hommes parmi les malades R. Ainsi, sur les
315 malades S, 199 (63 %) étaient de sexe masculin,
contre 18 sur 20 malades R; 113 des 199 males S (57%),
contre 15 des 18 mâles R, avaient moins de 35 ans.
L’activité de la catalase des bacilles provenant des
malades S avant traitement était, dans l’ensemble, plus
élevée que celle des bacilles des malades R, mais il
n’y avait pas de difference dans leur virulence pour le
cobaye.
Quatre-vingt-dix malades S et 6 malades R ont été
traités par l’isoniazide+PAS, 225 malades S et 14
malades R par l’isoniazide seul, en trois posologies
différentes. Le traitement a été administré pendant une
année.
A la fin des 12 mois de traitement, 8 des 86 malades S
(isoniazide+PAS), soit 9%, contre 5 des 6 malades R
(83%), n’avaient pas réagi favorablement, d’après le
critère bactériologique. Parallèlement, 93 des 216 mala-
des S (43%) traités à l’isoniazide seul, et 12 des 14 mala-
des R soumis aux mêmes regimes, n’avaient pas réagi
favorablement non plus, d’après le critère bactériologique.
Ces différences, dans les deux séries, sont statistiquement
significatives. (Les malades décédés à la suite d’autres
maladies que la tuberculose et ceux pour qui la théra-
peutique a été changée en raison de la toxicité du médica-
ment, ont été exclus des statistiques.)
Si l’on considère les progrès que montre l’examen
radiologique effectué par un observateur indépendant,
les changements de poids et de vitesse de sedimentation
des érythrocytes, l’amélioration des malades R, au cours
de la premiere année, était à peu près la même que celle
des malades S; mais les aggravations, révélée radiologi-
quement, survinrent plus tard.
Des faits militent en faveur de l’idée que la réponse
des malades R était bien due à la chimiothérapie.
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